BioPharmSignal logoBioPharmSignal

Biotech News

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

bioAffinity Technologies, Inc. (BIAF)bioAffinity Technologies, Inc.Company update

BIAF (BIAF) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is biaf.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BIAFbioAffinity Technologies, Inc.2026-07-27 12:08 EST

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

BIAFbioAffinity Technologies, Inc.2026-08-07 12:00 EST

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

OSUROraSure Technologies, Inc.2026-06-11 12:00 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

FATEFate Therapeutics2026-06-01 12:30 EST

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

View all latest news

bioAffinity Technologies, Inc.

Noninvasive Lung Diagnostics bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease. Its approach uses flow-cytometry and artificial-intelligence analysis of cells collected from sputum samples. CyPath Lung CyPath Lung is a laboratory-developed test intended to help assess...

Recent company news

BIAFbioAffinity Technologies, Inc.2026-08-07 12:00 EST

bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

BIAFbioAffinity Technologies, Inc.2026-07-27 12:08 EST

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

BIAFbioAffinity Technologies, Inc.2026-07-22 12:08 EST

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

BIAFbioAffinity Technologies, Inc.2026-07-07 12:46 EST

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

BIAFbioAffinity Technologies, Inc.2026-06-22 12:00 EST

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

Stock data

Close
0.53 USD
Market cap
7.62M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States